基于网络药理学的侯氏黑散抗缺血性脑卒中机制研究

doi:10.3969/j.issn.1006-7795.2021.01.008

摘要/Abstract

摘要： 目的应用网络药理学方法分析侯氏黑散抗脑缺血的核心组分及分子机制。方法通过侯氏黑散活性成分筛选、成分靶点和疾病靶点挖掘,建立并分析“成分-靶点”网络得到药效成分及药效靶点。构建蛋白相互作用(protein-protein interaction,PPI)网络进行京都基因和基因组百科全书(Kyoto Encyclopedia of Genes and Genomes,KEGG)通路富集分析,找出潜在信号通路。结果筛选得到了侯氏黑散抗脑缺血的5个有效成分:β-谷甾醇、隐品碱、原阿片碱、豆甾醇、山姜素;22个药效靶点:雌激素受体1(estrogen receptor, ESR1)、雄激素受体(androgen receptor, AR)、前列腺素G/H合酶2(prostaglandin G/H synthase 2, PTGS2)、凝血酶原2(prothrombin, F2)、内皮型一氧化氮合酶(nitric oxide synthase, endothelial, NOS3)等。基于PPI网络,侯氏黑散抗脑缺血的靶点显著富集于流体剪切应力通路、晚期糖基化终产物-晚期糖基化终产物受体(advanced glycation end products/receptor for advanced glycation end products, AGE-RAGE)通路、缺氧诱导因子1-α/血管内皮生长因子(hypoxia inducible factor1-α/vascular endothelial growth factor, HIF1-α/VEGF)通路等。结论侯氏黑散抗脑缺血损伤主要通过影响炎性反应、血管新生、氧化应激等方面发挥作用,与多条信号通路存在直接或间接关系,具有多成分、多靶点、多途径的特点。

关键词: 网络药理学, 侯氏黑散, 缺血性脑卒中, 分子机制

Abstract: Objective To analyze the core components and possible molecular mechanisms of Houshiheisan in the treatment of cerebral ischemia by network pharmacological method. Methods Through active components screening, components targets and disease targets prediction of Houshiheisan, the “component-target” network was established and analyzed to obtain the effective components and targets. Protein-protein interaction(PPI) network was constructed for Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to identify potential signal pathways. Results Five effective components of Houshiheisan against cerebral ischemia, including β-Sitosterol, cryptopine, fumarine, stigmasterol, and (2R)-7-hydroxy-5-methoxy-2-phenylchroman-4-one, and 22 important anti-cerebral ischemia targets, including estrogen receptor(ESR1), androgen receptor(AR), prostaglandin G/H synthase 2(PTGS2), prothrombin(F2), nitric oxide synthase, endothelial(NOS3), etc. were found. Based on the PPI results, pharmacological targets of Houshiheisan treating cerebral ischemia might have a close relationship with the fluid shear stress pathway, advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) pathway, and hypoxia inducible factor1-α/vascular endothelial growth factor(HIF1-α/VEGF) pathway, etc. Conclusion Houshiheisan for treatment of ischemic stroke mainly plays a role in regulating inflammation, angiogenesis, and oxidative stress. It holds direct or indirect relationships with multiple signal pathways and has the characteristics of multi-components, multi-targets, and multi-pathways.

Key words: network pharmacology, Houshiheisan, ischemic stroke, molecular mechanism

中图分类号:

R229

王璇, 马重阳, 张雅文, 程宏发, 张秋霞. 基于网络药理学的侯氏黑散抗缺血性脑卒中机制研究[J]. 首都医科大学学报, 2021, 42(1): 43-52.

Wang Xuan, Ma Chongyang, Zhang Yawen, Cheng Hongfa, Zhang Qiuxia. A network pharmacology approach to uncover the molecular mechanisms of Houshiheisan for treatment of ischemic stroke[J]. Journal of Capital Medical University, 2021, 42(1): 43-52.

参考文献

[1] Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480-687 adults[J].Circulation, 2017,135(8):759-771.
[2] 张仲景.金匮要略[M].北京:中国医药科技出版社,2016:21-26.
[3] 陆跃,姚晓泉,常佳慧,等.张仲景脑中风治略思想探究[J].中华中医药杂志,2017,32(3):1197-1200.
[4] 邓明华.侯氏黑散治疗脑缺血性中风后遗症20例临床观察[J].中医药导报,2009,15(12):21-22.
[5] 蔡忠彪,李应宏.侯氏黑散配合西药治疗急性缺血性脑中风45例[J].中国中医药现代远程教育,2015,13(18):140-141.
[6] 韩艳秋.侯氏黑散加减对缺血性脑卒中二级预防临床观察[J].辽宁中医药大学学报,2018,20(3):14-16.
[7] Lu Y, Hsiang F, Chang J H, et al. Houshiheisan and its components promote axon regeneration after ischemic brain injury[J].Neural Regen Res, 2018, 13(7):1195-1203.
[8] Chang J, Yao X, Zou H, et al. BDNF/PI3K/Akt and Nogo-A/RhoA/ROCK signaling pathways contribute to neurorestorative effect of Houshiheisan against cerebral ischemia injury in rats[J].J Ethnopharmacol, 2016, 194:1032-1042.
[9] Wang H, Wang L, Zhang N, et al. Houshiheisan compound prescription protects neurovascular units after cerebral ischemia. [J].Neural Regen Res, 2014, 9(7):741-748.
[10]Xiang Y, Yao X, Wang X, et al. Houshiheisan promotes angiogenesis via HIF-1α/VEGF and SDF-1/CXCR4 pathways: in vivo and in vitro[J].Biosci Rep, 2019, 39(10):BSR20191006.
[11]刘志华,孙晓波.网络药理学:中医药现代化的新机遇[J].药学学报,2012,47(6):696-703.
[12]Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application[J].Chin J Nat Meds, 2013, 11(2):110-120.
[13]Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks[J].Methods Mol Biol, 2011,696:291-303.
[14]凌志峰,黄斌,鲜慈英,等.基于网络药理学探析黄芩在抗抑郁方面的作用机制[J].湖北民族学院学报(医学版),2019,36(4):1-6.
[15]Xie C, Mao X, Huang J, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases[J].Nucleic Acids Res, 2011,39(Web Server issue):W316-322.
[16]刘磊,刘丽华,马玉奎.脑缺血再灌注损伤机制研究进展[J].药学研究,2016,35(9):542-544.
[17]Jiang X, Andjelkovic A V, Zhu L, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke[J]. Prog Neurobiol,2018,163-164:144-171.
[18]张秋霞.侯氏黑散治疗中风后遗症的机理探讨[J].北京中医,2002,21(4):242-243.
[19]李铮,张解玉,姚子昂,等.基于网络药理学分析人参-黄芪治疗肺癌潜在靶点和机制[J].中国实验方剂学杂志,2020,26(4):207-213.
[20]李亚敏,周祯祥,韩林涛,等.基于网络药理学的细辛-干姜药对作用机制研究[J].时珍国医国药,2019,30(3):726-730.
[21]谢心美,郝海鑫,何剑斌.植物甾醇的生理功能及其应用[J].草业科学,2013,30(12):2105-2109.
[22]Jiang Y H, Li X, Niu W, et al. β-sitosterol regulated microRNAs in endothelial cells against an oxidized low-density lipoprotein[J].Food Funct, 2020,11(2):1881-1890.
[23]Adebiyi O E, Olopade J O, Olayemi F O. Sodium metavanadate induced cognitive decline, behavioral impairments, oxidative stress and down regulation of myelin basic protein in mice hippocampus: Ameliorative roles of β-spinasterol, and stigmasterol[J].Brain Behav, 2018, 8(7):e01014.
[24]Alam M B, Ju M K, Kwon Y G, et al. Protopine attenuates inflammation stimulated by carrageenan and LPS via the MAPK/NF-κB pathway[J].Food Chem Toxicol, 2019, 131:110583.
[25]Aneja R, Katyal A, Chandra R. Stimulation of lipid peroxidation and impairment of glutathione-dependent defense system in Wistar rats treated with cryptopine, a rare non-narcotic opium alkaloid[J]. Eur J Drug Metab Pharmacokinet,2004, 29(1):31-36.
[26]胡柯,钱红,刘理静,等.MeCP2促进山姜素对鼠巨噬细胞炎性因子表达的抑制及其分子机制[J].现代免疫学,2019,39(4):271-276.
[27]Selvaraj U M, Zuurbier K R, Whoolery C W, et al.Selective nonnuclear estrogen receptor activation decreases stroke severity and promotes functional recovery in female mice[J].Endocrinology, 2018,159(11):3848-3859.
[28]张雪姣,季晖,唐苏苏,等.雌激素受体在中枢神经系统疾病中的作用[J].药学研究,2018,37(4):221-225,248.
[29]Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective[J].Br J Clin Pharmacol,2016,82(4):957-964.
[30]秦臻,张彦燕,韦正新,等.当归补血汤在流体剪切应力环境中对内皮细胞功能的影响[J].北京中医药大学学报,2018,41(8):630-635.
[31]Zhou J, Li Y S, Chien S. Shear stress-initiated signaling and its regulation of endothelial function[J].Arterioscler Thromb Vasc Biol, 2014,34(10):2191-2198.
[32]Chen Y J, Chan D C, Chiang C K, et al. Advanced glycation end-products induced VEGF production and inflammatory responses in human synoviocytes via RAGE-NF-κB pathway activation[J]. J Orthop Res, 2016,34(5):791-800.
[33]Hansen L M, Gupta D, Joseph G, et al. The receptor for advanced glycation end products impairs collateral formation in both diabetic and non-diabetic mice[J]. Lab Invest, 2017,97(1):34-42.